Welcome to our dedicated page for TC BioPharm (Holdings) plc American Depositary Shares news (Ticker: $TCBP), a resource for investors and traders seeking the latest updates and insights on TC BioPharm (Holdings) plc American Depositary Shares stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect TC BioPharm (Holdings) plc American Depositary Shares's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of TC BioPharm (Holdings) plc American Depositary Shares's position in the market.
TC BioPharm (Holdings) plc announced the exercise of warrants for £3.1 million gross proceeds. The Company entered into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase 1,750,000 of the Company's American Depositary Shares. The gross proceeds are expected to be approximately £3.1 million. In return for the exercise of the warrants, the Company will issue new unregistered warrants to purchase 3,500,000 shares of common stock. The offering is expected to close on May 8, 2024. The net proceeds will be used to support an upcoming clinical trial on Acute Myeloid Leukemia.
TC BioPharm (NASDAQ: TCBP) announced the execution of a non-binding letter of intent to acquire a biotechnology company focusing on CAR-T therapies for refractory cancers and solid tumors. The acquisition target has proven the therapeutic potential of its lead CAR-T candidate for various solid tumors and is also developing a novel allogeneic CAR-T for autoimmune diseases. The potential acquisition aims to expand TC BioPharm's therapeutic platform and bring synergies in CAR development expertise, providing multiple shots on goal for the treatment of various indications.